In vitro activity of RX-P873 against enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 4, 2015, Pages 2280-2285

  Flamm, Robert K ^a   Rhomberg, Paul R ^a   Jones, Ronald N ^a,b   Farrella, David J ^a,c  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFTAZIDIME; COLISTIN; MEROPENEM; RX P 873; TOBRAMYCIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; GUANIDINE DERIVATIVE; PYRIMIDINONE DERIVATIVE; RX-P873;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BINDING AFFINITY; BROTH DILUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENCY; ENTEROBACTERIACEAE; EUROPE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORTH AMERICA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; CHEMISTRY; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; ENTEROBACTERIACEAE; GUANIDINES; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PYRIMIDINONES;

EID: 84928922795     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04840-14     Document Type: Article

References (22)

1. Cohen J. 2013. Confronting the threat of multidrug-resistant Gramnegative bacteria in critically ill patients. J Antimicrob Chemother 68: 490-491. http://dx.doi.org/10.1093/jac/dks460.
2. De Kraker ME, Wolkewitz M, Davey PG, Koller W, Berger J, Nagler J, Icket C, Kalenic S, Horvatic J, Seifert H, Kaasch A, Paniara O, Argyropoulou A, Bompola M, Smyth E, Skally M, Raglio A, Dumpis U, Melbarde Kelmere A, Borg M, Xuereb D, Ghita MC, Noble M, Kolman J, Grabljevec S, Turner D, Lansbury L, Grundmann H. 2011. Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother 66:398-407. http://dx.doi.org/10.1093/jac/dkq412.
3. Kallen AJ, Hidron AI, Patel J, Srinivasan A. 2010. Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008. Infect Control Hosp Epidemiol 31:528-531. http://dx.doi.org/10.1086/652152.
4. Fauci AS, Morens DM. 2012. The perpetual challenge of infectious diseases. N Engl J Med 366:454-461. http://dx.doi.org/10.1056/NEJMra1108296.
5. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12. http://dx.doi.org/10.1086/595011.
6. Boucher HW, Talbot GH, Benjamin DK, Jr, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D, Infectious Diseases Society of America. 2013. 10 × '20 progress-development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 56:1685-1694. http://dx.doi.org/10.1093/cid/cit152.
7. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/drugresistance/threat-report-2013/. Accessed 24 September 2014.
8. Scheideman M, Bhattacharjee A, Chen S, Collin F, Dalton J, Devito J, Devivo M, Kanyo Z, Leggio M, Lou R, O'Dowd H, Paik I, Remy J, Sinishtaj S, Wimberly B, Duffy E. 2011. Completely novel antibiotics for treating multidrug-resistant Gram-negative infections: the phenoxazinocytosines, abstr F1-1844. Abstr 51st Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
9. Sinishtaj S, Bhattacharjee A, Chen S, Collin F, Dalton J, Devito J, Devivo MD, Ippolito YJ, Kanyo Z, Leggio M, Lou R, O'Dowd H, Paik I, Remy J, Scheideman M, Tang Y, Wimberly B, Duffy E. 2011. Completely novel antibiotics for treating multidrug-resistant Gram-nega tiveinfections: the isocytosines, abstr F1-1845. Abstr 51st Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
10. Bhattacharjee A, Chen S, Collin F, Dalton J, Devito J, Devivo M, Kanyo Z, Leggio M, Lou R, O'Dowd H, Paik I, Remy J, Scheideman M, Sinishtaj S, Tang Y, Wimberly B, Duffy E. 2011. Completely novel antibiotics for treating multidrug-resistant Gram-negative infections: the pyrrolocytosines, abstr F1-1846. Abstr 51st Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
11. Flamm RK, Rhomberg PR, Jones RN, Farrell DJ, Duffy E. 2014. In vitro activity of RX-P873 tested against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter spp., abstr 1555b. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
12. Marra A, Bortolon E, Molstad D, Wu Y, Jing H, Duffy E. 2011. Novel ribosome inhibitors are efficacious in a murine skin and soft tissue infection model caused by Klebsiella pneumoniae, abstr F1-1853. Abstr 51st Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
13. Marra A, Bortolon E, Molstad D, Wu Y, Jing H, Duffy E. 2011. Novel ribosome inhibitors are efficacious in a murine kidney infection model caused by Staphylococcus aureus MRSA USA300, abstr F1-1852. Abstr 51st Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
14. Marra A, Bortolon E, Molstad D, Wu Y, Jing H, Duffy E. 2011. Novel ribosome inhibitors are efficacious in a murine peritonitis model caused by different bacterial pathogens, abstr F1-1854. Abstr 51st Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
15. Marra A, Bortolon E, Molstad D, Wu Y, Jing H, Duffy E. 2012. Novel ribosome inhibitors are efficacious in a murine respiratory tract infection model caused by Streptococcus pneumoniae, abstr F-1523. Abstr 52nd Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
16. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
17. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
18. Duffy E, Devivo M, Kanyo Z, Bhattacharjee A. 2011. The molecular tuning of RX-04, a novel broad spectrum antibacterial class, for coverage of MDR Gram-negative pathogens, abstr F1-1843. Abstr 51st Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
19. Hershfield J, Miller L, Halasohoris S, Marchand C, Remy J, Leggio M, Devito J, Bhattacharjee A, Marra A, Kanyo Z, Duffy E. 2012. Antibacterial activity of novel RX-04 compounds against biodefense pathogens, abstr F-1522. Abstr 52nd Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
20. Hershfield J, Miller L, Halasohoris S, Miller J, Schmadel H, Poinsette J, Wasbrough E, Leggio M, Kanyo Z, Duffy E. 2013. Optimization of novel RX-04 compounds against biodefense pathogens, abstr F-635. Abstr 53rd Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
21. Lamb LM, Crandon JL, Nicolau DP. 2013. Pharmacokinetic and pharmacodynamic evaluation of P-873 versus Klebsiella pneumoniae in a neutropenic murine thigh infection model. Antimicrob Agents Chemother 57:1971-1973. http://dx.doi.org/10.1128/AAC.02170-12.
22. Pfizer. 2013. Tygacil product insert. Pfizer, New York, NY.